secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2025-09-15T23:59:59+00:00
Accession:  0001213900-25-087461
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Therapeutics acquires eXIthera's Factor XIa inhibitors for up to $15M in milestones
--------------------------------------------------------------------------------

- Acquires frunexian (Phase 2-ready IV FXIa) and EP-7327 (IND-ready oral FXIa) from eXIthera.
- Total contingent milestone payments up to $15M plus royalties on global sales; $50K cash paid at closing.
- Deal closed September 12, 2025; Cadrenal now sole developer of both a VKA (tecarfarin) and FXIa inhibitors.
- Plans Phase 2 study for frunexian in complex cardiac surgery with first patient expected in 1Q27.
- eXIthera to receive 2% royalty on net sales outside China and 50% of sublicense royalties from Haisco.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390025087461/0001213900-25-087461-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390025087461/ea0257138-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-087461

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer